The 40th annual SLEEP meeting drew its usual crowd of clinicians, researchers, technologists, and industry representatives to Baltimore — but this year’s meeting felt different in at least one important way. The pharmaceutical presence on the exhibit floor and in sponsored symposia has grown substantially over the past decade, and SLEEP 2026 made that shift impossible to ignore.
That’s not a criticism. It reflects genuine progress. Conditions like narcolepsy and idiopathic hypersomnia now have real treatment options where there were few before, and the science behind them is advancing quickly. The most-watched story coming out of Baltimore was Takeda’s continued development of oveporexton (TAK-861), an orexin receptor 2 agonist targeting narcolepsy type 1. Unlike existing therapies that manage symptoms, oveporexton is designed to address the underlying orexin deficiency driving the disorder. Data presented at the meeting showed improvements in wakefulness, cataplexy control, cognitive performance, and sleep quality — and the buzz in the room reflected how significant that could be. Jazz Pharmaceuticals and Harmony Biosciences also had strong presences, with new data on Xywav® and pitolisant respectively.
On the device side, home sleep testing continues to be one of the most active product categories in the industry, and that was evident throughout the exhibit hall. But the product generating the most conversation this year was the KPAP from SleepRes — a noteworthy addition to the PAP therapy landscape that drew considerable attention from attendees.
AI and consumer wearables rounded out the major themes. Sleep staging algorithms, clinical decision support tools, and workflow automation all had representation, and the conversation around integrating consumer-generated data into clinical practice has matured noticeably. Patients are arriving at sleep clinics with months of wearable data — the question now isn’t whether that data matters, but how to use it well.
The 40th anniversary added some welcome perspective. Sleep medicine has come a long way, and SLEEP 2026 was a reminder of how much is still moving.
